

Title (en)  
PRODRUGS OF FULVESTRANT

Title (de)  
PRODRUGS VON FULVESTRANT

Title (fr)  
PROMÉDICAMENTS DE FULVESTRANT

Publication  
**EP 4061376 A4 20240313 (EN)**

Application  
**EP 20891095 A 20201124**

Priority  
• IN 201921047986 A 20191124  
• IN 202021029084 A 20200708  
• IB 2020061065 W 20201124

Abstract (en)  
[origin: WO2021100029A2] The present invention relates to Fulvestrant prodrugs and process for the preparation thereof. The present disclosure also relates to pharmaceutical composition of Fulvestrant prodrugs and method of treatment using the same.

IPC 8 full level  
**C07J 31/00** (2006.01); **A61K 31/565** (2006.01); **A61P 35/00** (2006.01); **C07J 41/00** (2006.01); **C07J 43/00** (2006.01); **C07J 51/00** (2006.01)

CPC (source: EP US)  
**A61P 35/00** (2018.01 - EP); **C07J 31/006** (2013.01 - EP US); **C07J 41/0072** (2013.01 - EP US); **C07J 43/003** (2013.01 - EP US);  
**C07J 43/006** (2013.01 - US); **C07J 51/00** (2013.01 - EP)

Citation (search report)  
• [XYI] WO 2015038649 A1 20150319 - SYNTA PHARMACEUTICALS CORP [US]  
• [XYI] WO 2013158644 A2 20131024 - SYNTA PHARMACEUTICALS CORP [US]  
• [XYI] WO 2019050850 A1 20190314 - PRIMETIME LIFE SCIENCES LLC [US]  
• [XP] WO 2019224790 A2 20191128 - KASHIV BIOSCIENCES LLC [US]

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**WO 2021100029 A2 20210527; WO 2021100029 A3 20210701**; AU 2020386864 A1 20220616; CA 3162182 A1 20210527;  
CN 115151260 A 20221004; EP 4061376 A2 20220928; EP 4061376 A4 20240313; JP 2023503898 A 20230201; US 2023137764 A1 20230504

DOCDB simple family (application)  
**IB 2020061065 W 20201124**; AU 2020386864 A 20201124; CA 3162182 A 20201124; CN 202080093658 A 20201124;  
EP 20891095 A 20201124; JP 2022529452 A 20201124; US 202017779015 A 20201124